Exhibit 99.2 MAY 1, 2024 GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation's recent financial and operational performance and general business outlook. | Date: | May 1, 2024 | | --- | --- | | Time: | 4:30 p.m. ET / 1:30 p.m. PT | | Dial-in numbers: | 1-888-210-2212 (U.S.), 1-646-960-0390 (International) | ...

Shares of Glaukos Corporation (GKOS) scaled a new 52-week high of $97.77 on Apr 5, before closing the session slightly lower at $96.77.Over the past year, this Zacks Rank #3 (Hold) stock has surged 98.8% compared with the 8.6% rise of the industry and the S&P 500’s 27.1% growth.The company’s expected growth rate of 3.9% for 2024 compares with the industry’s growth projection of 13.5%. Glaukos’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average ...

Glaukos Corporation (GKOS) recently announced that its prostaglandin analog iDose TR (travoprost intracameral implant) 75 mcg was assigned permanent Healthcare Common Procedure Coding System J-code by the U.S. Centers for Medicare and Medicaid Services (CMS). This prostaglandin analog is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.The new J-code for iDose TR, J7355, is likely to become effective starting Jul 1, 2024. It is expected to ...

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this currently Zacks Rank #3 (Hold) company have risen 15.3% in the past six months compared with the industry’s 13.6% growth. The S&P 500 Index has also increased 12.7% in the same time frame.Glaukos, with a market capitalization of $4.3 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) Delaware 33-0945406 (State or other ...

Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Conference Call February 21, 2024 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Thomas W. Burns - Chairman and Chief Executive Officer Joseph E. Gilliam - President and Chief Operating Officer Alex R. Thurman - Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Margaret Kaczor - William Blair Allen ...

Glaukos Corporation (NYSE:GKOS) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - Chairman & Chief Executive Officer Joe Gilliam - President & Chief Operating Officer Alex Thurman - Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Joanne Wuensch - Citigroup David Saxon - Needham Allen Gong - JPMorgan Anthony Petrone - Mizuho Group George Sellers - ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

Glaukos Corporation (NYSE:GKOS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Christopher Lewis - VP, IR & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Alex Thurman - SVP & CFO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company Ryan Zimmerman - BTIG Charles Ellson - Wells Fargo Securities Joseph Conway - Needham & Company Joanne Wuensch - Citigroup George Sellers - Stephens Inc. Phillip Dantoin - Piper Sandler & Co. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 33-0945406 (I.R.S. Emp ...